

The Gut Microbiota - The Environmental Causative Factor and the Potential Therapeutic Targets of Autism Spectrum Disorder

Jun Mei Zhou*

Shanghai Children's Hospital, Shanghai Jiaotong University, Shanghai, China

Autism spectrum disorder (ASD) is a neurodevelopmental mental disorder affecting approximately 1-2% of the population. ASD patients displayed a wide range of symptoms including social interaction difficulties, decreased communication skills, restricted activities and repetitive behavior [1]. The etiology of ASD involves both genetic and environmental factors according to previous research [2]. Up to now, more than 200 susceptible genes have been identified in ASD patients with different patterns of inheritance [3]. Meanwhile, the gut microbiota emerged as important environmental factors and played a pivotal role in the development and treatment of ASD.

The paediatricians first observed that ASD children frequently accompany with gastrointestinal symptoms [4]. Previous clinical and biological researches have demonstrated that the disturbance in the gut microbiota caused by antibiotic application served as a potential risk factor to the development of ASD [5-7]. The human gut harbors at least more than 1,000 different species of known bacteria [8]. The first colonization of the gut microbiota comes from a natural complex microbiota exposure when the infant is delivered vaginally [9]. The diet and other environmental factors including infection and subsequent antibiotics application definitely alter the natural composition of the gut microbiota [10]. Altered composition of the gut microbiota have been confirmed to be the causative factor for sorts of diseases including ASD. High-throughput sequencing identifies two predominant bacterial species in the human microbiota: the Bacteroidetes and Firmicutes phyla, with the Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia phyla occurring relatively rare [11]. Clostridia, Bacteroidetes and Desulfovibrio were proved to promote autistic behaviors in ASD [12-15]. In addition, the level of Bacteroidetes was found to be higher in the stools of severe ASD children, while as the level of Firmicutes higher in the control group. Also, short-chain fatty acids (SCFAs) played an important role during the processing [14,15].

The microbiota-gut-brain axis, a well-known neurohumoral communication system performs bidirectionally and its disturbance was found in ASD subjects [16]. According to previous research, the bidirectional microbiota-gut-brain axis mainly acts through neuroendocrine, neuroimmune and autonomic nervous mechanisms. Signals from the gut microbiota influence brain function through microbiota metabolites such as SCFAs [14,15]. Meanwhile, the brain sends messages to the gut to impact microbiota activity and gastrointestinal physiology through serotonin (5-hydroxytryptamine or 5-HT) and other neurotransmitters. 5-HT is a monoamine that plays an important regulatory role in many organ systems [17,18]. Previous research has demonstrated a direct metabolic signalling of gut microbiota to 5-HT release [19]. The gut microbiota can also act through SCFAs to promote the enteric 5-HT production and homeostasis [20]. In addition, recent publication reported specific finding in ASD that altered blood-brain barrier integrity could be couple with increased neuroinflammation which possibly impaired gut barrier integrity [21]. More research will be performed to elucidate the specific mechanisms of how gut microbiota imbalances lead to ASD and to provide potential therapeutic targets to ASD.

The potential therapeutic benefit of re-establishing the balance of

the gut microbiota was first demonstrated through mouse model of ASD [22-24]. The investigators applied a maternal immune activation (MIA) mouse model as ASD model and gave MIA offspring oral treatment of human commensal *Bacteroides fragilis*. The research demonstrated that the probiotic treatment could correct the gut permeability, alter the gut microbial composition, and ameliorate defects of the ASD mouse model in communicative ability, anxiety-like and sensorimotor behaviors, etc. [22]. The results supported the gut-microbiome-brain connection in the mouse model of ASD and identified a potential therapeutic target. Another recent report also indicated that maternal high-fat diet could induce a shift in gut microbial ecology and negatively impact offspring's ASD-like social behavior [25]. Clinical case study also observed reduced severity of abdominal symptoms and improvement of ASD core symptoms after a multi-strain mixture of ten probiotics treatment for 4 weeks and followed by a four month follow-up observation on a 12 year old boy with ASD and severe cognitive disabilities [26]. Taken together, application of probiotics and certain special diet supplement may be a promising strategy to treat ASD. More translational biomedical research including ASD models studies and long-term follow-up clinical research need to be developed and further researches are needed to elucidate the biological mechanisms and set up optimal treatment protocol for ASD [27].

Acknowledgement

This work was supported by funding from the National Natural Science Foundation of China (No. 81270742, 81370700), funding from Shanghai Municipal Commission of Health and Family Planning (201540389) and from Professional and Technical Services Platform for Biobank of Critical Disease in Shanghai (15DZ2292100).

References

1. Lai MC, Lombardo MV, Chakrabarti B, Baron-Cohen S (2013) Subgrouping the autism "spectrum": Reflections on DSM-5. *PLoS Biol* 11: e1001544.
2. Risch N, Hoffmann TJ, Anderson M, Croen LA, Grether JK, et al. (2014) Familial recurrence of autism spectrum disorder: Evaluating genetic and environmental contributions. *Am J Psychiatry* 171: 1206-1213.
3. Tordjman S, Somogyi E, Coulon N, Kermarrec S, Cohen D, et al. (2014) Gene × Environment interactions in autism spectrum disorders: Role of epigenetic mechanisms. *Front Psychiatry* 5: 53.
4. Mannion A, Leader G, Healy O (2013) An investigation of comorbid psychological disorders, sleep problems, gastrointestinal symptoms and epilepsy in children and adolescents with autism spectrum disorder. *Res Autism Spectr Disord* 7: 35-42.

*Corresponding author: Jun Mei Zhou, Department of Central Laboratory, Shanghai Children's Hospital, Shanghai Jiaotong University, 1400 Beijing Road West, Jingan District, Shanghai 200040, China, Tel: +86-21-52136744; E-mail: junmei_zhou@139.com

Received December 27, 2016; Accepted January 09, 2017; Published January 16, 2017

Citation: Zhou JM (2017) The Gut Microbiota - The Environmental Causative Factor and the Potential Therapeutic Targets of Autism Spectrum Disorder. *J Alzheimers Dis Parkinsonism* 7: 297. doi: 10.4172/2161-0460.1000297

Copyright: © 2017 Zhou JM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

5. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA (2011) Gastrointestinal flora and gastrointestinal status in children with autism--comparisons to typical children and correlation with autism severity. *BMC Gastroenterol* 11: 22-35.
6. Critchfield JW, van Hemert S, Ash M, Mulder L, Ashwood P (2011) The potential role of probiotics in the management of childhood autism spectrum disorders. *Gastroenterol Res Pract* 2011: 161358.
7. de Theije CG, Koelink PJ, Korte-Bouws GA, Lopes da Silva S, Korte SM, et al. (2014) Intestinal inflammation in a murine model of autism spectrum disorders. *Brain Behav Immun* 37: 240-247.
8. Bermon S, Petriz B, Kajėnienė A, Prestes J, Castell L, et al. (2015) The microbiota: An exercise immunology perspective. *Exerc Immunol Rev* 21: 70-79.
9. Di Mauro A, Neu J, Riezzo G, Raimondi F, Martinelli D, et al. (2013) Gastrointestinal function development and microbiota. *Ital J Pediatr* 39: 15.
10. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, et al. (2012) Host-gut microbiota metabolic interactions. *Science* 336: 1262-1267.
11. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, et al. (2005) Diversity of the human intestinal microbial flora. *Science* 308: 1635-1638.
12. Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, et al. (2010) Pyrosequencing study of fecal microflora of autistic and control children. *Anaerobe* 16: 444-453.
13. Finegold SM, Downes J, Summanen PH (2012) Microbiology of regressive autism. *Anaerobe* 18: 260-262.
14. MacFabe DF (2012) Short-chain fatty acid fermentation products of the gut microbiome: Implications in autism spectrum disorders. *Microb Ecol Health Dis* 23: 19260-19284.
15. MacFabe DF (2015) Enteric short-chain fatty acids: Microbial messengers of metabolism, mitochondria, and mind: Implications in autism spectrum disorders. *Microb Ecol Health Dis* 26: 28177-28191.
16. Bauer KC, Huus KE, Finlay BB, et al. (2016) Microbes and the mind: Emerging hallmarks of the gut microbiota-brain axis. *Cell Microbiol* 18: 632-644.
17. Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, et al. (2014) Mini review: Gut microbiota: The neglected endocrine organ. *Mol Endocrinol* 28: 1221-1238.
18. Luo J, Feng J, Liu S, Walters ET, Hu H (2015) Molecular and cellular mechanisms that initiate pain and itch. *Cell Mol Life Sci* 72: 3201-3223.
19. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, et al. (2015) Indigenous bacteria from the gut microbiota regulates host serotonin biosynthesis. *Cell* 161: 264-276.
20. Reigstad CS, Salmons CE, Rainey JF III, Szurszewski JH, Linden DR, et al. (2015) Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. *FASEB J* 29: 1395-1403.
21. Fiorentino M, Sapone A, Senger S, Camhi SS, Kadziński SM, et al. (2016) Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. *Mol Autism* 7: 49.
22. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, et al. (2013) Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell* 155: 1451-1463.
23. Malkki H (2014) Neurodevelopmental disorders: Human gut microbiota alleviate behavioural symptoms in a mouse model of autism spectrum disorder. *Nat Rev Neurol* 10: 60.
24. Gilbert JA, Krajmalnik-Brown R, Porazinska DL, Weiss SJ, Knight R (2013) Toward effective probiotics for autism and other neurodevelopmental disorders. *Cell* 155: 1446-1448.
25. Buffington SA, Di Prisco GV, Auchtung TA, Ajami NJ, Petrosino JF, et al. (2016) Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. *Cell* 165: 1762-1775.
26. Grossi E, Melli S, Dunca D, Terruzzi V (2016) Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics. *SAGE Open Med Case Rep* 4: 2050313X16666231.
27. Slattey J, MacFabe DF, Frye RE (2016) The significance of the enteric microbiome on the development of childhood disease: A review of prebiotic and probiotic therapies in disorders of childhood. *Clin Med Insights Pediatr* 10: 91-107.

Citation: Zhou JM (2017) The Gut Microbiota - The Environmental Causative Factor and the Potential Therapeutic Targets of Autism Spectrum Disorder. *J Alzheimers Dis Parkinsonism* 7: 297. doi: [10.4172/2161-0460.1000297](https://doi.org/10.4172/2161-0460.1000297)

OMICS International: Open Access Publication Benefits & Features

Unique features:

- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

Special features:

- 700+ Open Access Journals
- 50,000+ editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at major indexing services
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission/>